Request to Join
has invited you to join this group
Naveed Sattar is a clinically active academic experienced in epidemiology, biomarkers and trials investigating the causes and consequences of diabetes, obesity and heart disease. He has published over 650 papers has received several national and international prizes for his research, and is amongst the most highly cited clinical academics in the world according to Thomson Reuters in 2016.
He has been on several guideline committees and is currently involved in several lifestyle and drug trials in diabetes and cardiovascular disease and leads on biomarker initiatives in several of these. He is also on Editorial or International advisory boards for Diabetologia, Lancet Diabetes and Endocrinology, BMC Medicine and UK Biobank, and is an Associate Editor for Circulation.
Dr. Darren K. McGuire, MD, MHSc is Professor of Medicine at UT Southwestern Medical Center in Dallas, Texas in the Division of Cardiology, where he holds the Dallas Heart Ball Chair for Research on Heart Disease in Women and is a Distinguished Teaching Professor. Dr. McGuire is the Lead Physician of the Parkland Hospital and Health System Cardiology clinics.
Training: MD-Johns Hopkins 1993 (AOA)
Intern/Resident-UT Southwestern Medical Center at Dallas
Cardiology Fellowship-Duke University
MHSc-Clinical Research-Duke University School of Medicine 2001
Dr. McGuire’s expertise is in large scale clinical trial design and execution, and drug registration/regulation, with a focus in the area of diabetes and cardiovascular disease. He presently has leadership roles for numerous international cardiovascular clinical outcomes trials, including T2DM, obesity, and lipid trials.
Dr. McGuire has been awarded UT Southwestern Outstanding Teacher awards from the internal medicine housestaff (2006), medical school class of 2008, and cardiology fellowship (2012), as well as the University of Texas System Board of Regents Outstanding Teacher Award 2013.
Dr. McGuire is a previous member of the FDA Cardiovascular and Renal Drugs Advisory Committee and remains an FDA ad hoc consultant. He is Deputy Editor of Circulation and Senior Editor of Diabetes and Vascular Disease Research. He has previously has been associate editor of the American Heart Journal, associate editor of Obesity, and co-editor of the textbook: Diabetes in Cardiovascular Disease: A Companion to Braunwald’s Heart Disease. Dr. McGuire has authored/co-authored over 240 peer-reviewed manuscripts, reviews, editorials and book chapters.
Soffia Gudbjörnsdottir has the primary responsibility for The Swedish National Diabetes Register (NDR). She is also an active participant in drawing up the national guidelines for diabetes care, a commission on behalf of the Swedish National Board of Health and Welfare. The NDR is a nationwide system for quality assurance and has been developed to stimulate more active and open use of real world data in order to improve diabetes care.
Soffia Gudbjörnsdottir is a coauthor of more than 130 publications with a focus on the gap between the guidelines and reality, the importance of risk factor control and morbidity and mortality in diabetes
Aidin Rawshani, MD, Sahlgrenska University hospital, began with his master thesis during his third term at medical school, Gothenburg University, where he studied the association between type 2 diabetes and diastolic dysfunction in young adults with heart failure. Shortly thereafter, he initiated his doctorate studies at the Swedish National Diabetes Registry (NDR), and Gothenburg University, Sahlgrenska Academy.
His research focuses on the epidemiological aspects of cardiovascular morbidity and mortality among individuals with diabetes, and the relative importance of cardiovascular riskfactors. He intends to evaluate the impact of the development of clinical care for patients with diabetes by examining long-term trends of diabetes-related complications and mortality among individuals with diabetes, compared with contemporary trends for matched controls from the general population. He also intends to investigate whether excess risk of mortality and cardiovascular disease can be eliminated by means of optimal risk factor control, the benefits of multiple risk factor control, the optimal level for each risk factor and which risk factor that appears to be most important in reducing risk for mortality and cardiovascular disease, and thus most relevant to target in primary prevention, in patients with type 1 and type 2 diabetes.